@article{975bc612c85348a8ad7cfdcad14565fe,
title = "A pilot study of clonidine plus physostigmine in alzheimer's disease",
abstract = "To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer{\textquoteright}s disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine plus clonidine. The Alzheimer{\textquoteright}s Disease Assessment Scale (ADAS) was used as the primary outcome measure. Neither physostigmine alone, nor the combination of physostigmine plus clonidine, was associated with a statistically significant improvement for the group. Three patients did show an improvement of at least 4 points on the total ADAS score with the drug combination. The implications of these results for treatment strategies are discussed.",
keywords = "Alzheimer{\textquoteright}s disease, Clonidine, Physostigmine",
author = "Bierer, {Linda M.} and Aisen, {Paul S.} and Michael Davidson and Ryan, {Theresa M.} and James Schmeidler and Davis, {Kenneth L.}",
year = "1994",
doi = "10.1159/000106731",
language = "אנגלית",
volume = "5",
pages = "243--246",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "5",
}